Skip to main content

Sleep Disorders

A label update for the insomnia drug Belsomra (suvorexant) C-IV adds study findings on its use in treating insomnia in patients with mild-to-moderate Alzheimer’s disease, drugmaker Merck announced.
The orexin receptor antagonist lemborexant (Dayvigo) has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults, Eisai Co. announced.
Treating depression in patients with comorbid insomnia is associated with improved insomnia symptoms, new research shows.
Karl Doghramji, MD, Medical Director of the Jefferson Sleep Disorders Center in Philadelphia shares tips for choosing insomnia treatments for older patients with dementia.
Adults who reported declining sleep quality in their 40s and 50s had more beta-amyloid protein in their brains later in life, positron emission tomography brain scans revealed.
Back to Top